

## AMENDMENTS TO THE CLAIMS:

1. (Canceled).

2. (Currently Amended) ~~The purified polypeptide of claim 1~~ A purified polypeptide that induces apoptosis of a neoplastic cell to which it binds, but does not induce apoptosis of a non-neoplastic cell, wherein said polypeptide specifically binds to ASPC-1 (ATCC Accession No. CRL-1682) and BXPC-3 (ATCC Accession No. CRL-1687) cells and not to non-neoplastic cells, ~~and~~ wherein said neoplastic cell is a ~~stomach adenocarcinoma~~, colorectal adenocarcinoma, squamous cell lung carcinoma, lung adenocarcinoma, squamous cell carcinoma of the esophagus, adenocarcinoma of the pancreas, adenocarcinoma of the prostate, ductal carcinoma of the breast, lobular carcinoma of the breast, adenocarcinoma of the ovary, or adenocarcinoma of the uterus cell, and wherein said polypeptide induces apoptosis of said neoplastic cell.

3. - 4. (Canceled).

5. (Currently Amended) A purified polypeptide ~~that~~ comprising a fragment that is at least 98% identical to the full length sequence of SEQ ID NO:1 or SEQ ID NO:3, wherein said polypeptide induces apoptosis of a neoplastic cell to which it binds, but does not induce apoptosis of a non-neoplastic cell, and wherein said polypeptide specifically binds to a stomach adenocarcinoma, colorectal adenocarcinoma, squamous cell lung carcinoma, lung adenocarcinoma, squamous cell carcinoma of the esophagus,

adenocarcinoma of the pancreas, urothel carcinoma of the urinary bladder, renal cell carcinoma of the kidney, adenocarcinoma of the prostate, ductal carcinoma of the breast, lobular carcinoma of the breast, adenocarcinoma of the ovary, adenocarcinoma of the endometrium, or adenocarcinoma of the uterus cell and not to a non-neoplastic cell.

6. (Canceled).

7. (Currently Amended) ~~The purified polypeptide of claim 6~~ A purified polypeptide that inhibits cell proliferation when bound to a neoplastic cell, but does not inhibit cell proliferation of a non-neoplastic cell, wherein said polypeptide specifically binds to ASPC-1 (ATCC Accession No. CRL-1682) and BXPC-3 (ATCC Accession No. CRL-1687) cells and not to non-neoplastic cells, and wherein said neoplastic cell is a stomach adenocarcinoma, colorectal adenocarcinoma, squamous cell lung carcinoma, lung adenocarcinoma, squamous cell carcinoma of the esophagus, adenocarcinoma of the pancreas, adenocarcinoma of the prostate, ductal carcinoma of the breast, lobular carcinoma of the breast, adenocarcinoma of the ovary, or adenocarcinoma of the uterus cell, and wherein said polypeptide inhibits cell proliferation of said neoplastic cell.

8. - 9. (Canceled).

10. (Currently Amended) A purified polypeptide ~~that~~ comprising a fragment that is at least 98% identical to the full length sequence of SEQ ID NO:1 or SEQ ID NO:3,

wherein said polypeptide inhibits cell proliferation when bound to a neoplastic cell, but does not inhibit cell proliferation of a non-neoplastic cell, and wherein said polypeptide specifically binds to a stomach adenocarcinoma, colorectal adenocarcinoma, squamous cell lung carcinoma, lung adenocarcinoma, squamous cell carcinoma of the esophagus, adenocarcinoma of the pancreas, urothel carcinoma of the urinary bladder, renal cell carcinoma of the kidney, adenocarcinoma of the prostate, ductal carcinoma of the breast, lobular carcinoma of the breast, adenocarcinoma of the ovary, adenocarcinoma of the endometrium, or adenocarcinoma of the uterus cell and not to a non-neoplastic cell.

11. (Currently Amended) The purified polypeptide of claim ~~1, 5, 6, or 10~~ 2, wherein said polypeptide comprises an antibody or a functional fragment thereof.

12. The purified polypeptide of claim 11, wherein said polypeptide is a functional fragment selected from the group consisting of V<sub>L</sub>, V<sub>H</sub>, F<sub>V</sub>, F<sub>C</sub>, Fab, Fab', and F(ab')<sub>2</sub>.

13. The purified polypeptide of claim 12, wherein said functional fragment comprises a fragment that is substantially identical to the sequence of SEQ ID NO:1 or SEQ ID NO:3.

14. The purified polypeptide of claim 13, wherein said functional fragment comprises a fragment that is substantially identical to a polypeptide comprising amino

acids 26-31, 49-51, and 88-95 of SEQ ID NO:1 or amino acids 11-18, 36-43, and 82-90 of SEQ ID NO:3.

15. - 18. (Canceled).

19. The purified polypeptide of claim 12, wherein said functional fragment comprises a fragment of the sequence of SEQ ID NO:1 or SEQ ID NO:3.

20. - 21. (Canceled).

22. (Currently Amended) The purified polypeptide of claim ~~1, 2, 5, 6, 7, or 10~~, 2, wherein said polypeptide comprises a sequence that is substantially identical to the amino acid sequence of SEQ ID NO:1.

23. (Currently Amended) The purified polypeptide of claim ~~1, 2, 5, 6, 7, or 10~~, 2, wherein said polypeptide comprises a sequence that is substantially identical to the amino acid sequence of SEQ ID NO:3.

24. (Currently Amended) The purified polypeptide of claim ~~1, 3, 5, 6, 8, or 10~~, 2, wherein said polypeptide comprises ~~a sequence that is substantially identical to the amino acid sequence of SEQ ID NO:5~~ SEQ ID NO:1.

25. (Currently Amended) The purified polypeptide of claim ~~1, 3, 5, 6, 8, or 10~~, 2, wherein said polypeptide comprises ~~a sequence that is substantially identical to the amino acid sequence of SEQ ID NO:7~~ SEQ ID NO:3.

26. - 40. (Canceled).

41. (Currently Amended) A purified polypeptide comprising amino acid 26-31, 49-51, and 88-95 of SEQ ID NO:1 ~~and or~~ amino acids 11-18, 36-43, and 82-90 of SEQ ID NO:3.

42. (Currently Amended) A The purified polypeptide of claim 41, wherein said polypeptide comprises amino acid 26-31, 49-51, and 88-95 of SEQ ID NO:1 ~~comprising the amino acid sequence of SEQ ID NOS:5 and 7~~.

43. (Currently Amended) A The purified polypeptide of claim 41, wherein said polypeptide comprises amino acids 11-18, 36-43, and 82-90 of SEQ ID NO:3 ~~comprising amino acids 26-34, 52-58, and 97-103 of SEQ ID NO:5 and amino acids 11-18, 36-43, and 82-100 of SEQ ID NO:7~~.

44. - 47. (Canceled).

48. (Currently Amended) ~~The purified polypeptide of claim 1, 2, 5, 6, 7, or 10,~~  
~~wherein said polypeptide is a polypeptide that is also~~ The antibody produced by the PM-1  
cell line having DSMZ Accession No. DSM ACC2599.

49. - 110. (Canceled).

111. (New) A purified antibody or functional fragment thereof, wherein said  
antibody or said functional fragment specifically binds a polypeptide having an  
approximate molecular weight of 35 or 65 kDa using sodium dodecyl sulfate  
polyacrylamide gel electrophoresis, and wherein said polypeptide is a polypeptide  
expressed by ASPC-1 (ATCC Accession No. CRL-1682) and BXPC-3 (ATCC Accession  
No. CRL-1687) cells and said polypeptide is not expressed by non-neoplastic cells of the  
same tissue type.

112. (New) The purified antibody or functional fragment thereof of claim 111,  
wherein said antibody or said functional fragment comprises a sequence that is  
substantially identical to the sequence of SEQ ID NO:1.

113. (New) The purified antibody or functional fragment thereof of claim 111,  
wherein said antibody or said functional fragment comprises a sequence that is  
substantially identical to the sequence of SEQ ID NO:3.